TRIGR Therapeutics, ABL Bio sign license deal for bispecific antibody candidate

Image: TR009 single agent clinical activity has been demonstrated across all dose levels among heavily pre-treated cancer patients with solid tumors including gastric, colon, GIST, and ovarian cancers. Photo: courtesy of dream designs / FreeDigitalPhotos.net.